Business Context and Reporting Period
This Form 8-K is filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on September 5, 2025. The filing addresses compliance with Nasdaq listing requirements regarding stockholders' equity.
Key Financial Metrics
- Stockholders' Equity: As of August 31, 2025, equity exceeds the Nasdaq minimum requirement of $2,500,000.
- Capital Raised (July 2025): Approximately $1.7 million gross proceeds from a registered direct offering and concurrent private placement of warrants.
- Capital Raised (August 2025): Approximately $5.35 million gross proceeds from a registered direct offering.
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide specific values for these metrics.
Material Changes
The Company previously received a Nasdaq deficiency notice on April 1, 2025, stating that stockholders' equity reported in the December 31, 2024, 10-K was below the $2,500,000 threshold. Following a compliance plan submitted on May 15, 2025, the Company executed two capital raising transactions in July and August 2025, resulting in stockholders' equity now meeting the listing standard.
Outlook, Risks, and Management Commentary
Management confirms that the recent capital raises have resolved the equity deficiency. The filing references an unaudited consolidated balance sheet as of August 31, 2025 (Exhibit 99.1) as evidence of compliance. No specific forward-looking guidance or new risk factors are detailed in this text beyond the resolution of the listing status.
Investor Verification Checklist
- Verify the exact stockholders' equity figure in the unaudited balance sheet (Exhibit 99.1) as of August 31, 2025.
- Confirm the dilution impact of the $1.7 million and $5.35 million offerings on existing shareholders.
- Review the terms of the warrants issued in the July 2025 transaction.
- Check for any subsequent Nasdaq communications confirming the restoration of full listing status.